207 results about "Hemophilias" patented technology

The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.

Specific amino acid loci of human fVIII interact with inhibitory antibodies of hemophilia patients after being treated with fVIII. Modified fVIII is disclosed in which the amino acid sequence is changed by multiple substitutions in human fVIII A2 and C2 domains. The modified fVIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.

The present invention is related to a novel composition of matter and methods of using the same. More particularly, the invention describes mutant human factor IX which has an increased resistance to inhibition by heparin. Methods of making and using this composition for the therapeutic intervention of hemophilia are disclosed.

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 μm or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale.

The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.

The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor IX or factor VIII genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor IX or factor VIII genes are also disclosed. The present invention is particularly useful for applications using gene therapy, in particular for the treatment of hemophilia A and B.

The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having improved FIX clotting activity. Three full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assays in FIX-depleted plasma. Two mutant proteins had increased specific FIX activity. Furthermore, a pre-activated FIX protein had an increased activity in FIX-depleted plasma. Therefore these FIX mutants can be used for the treatment of FIX associated bleeding disorders.

The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors. Therefore these FIX mutants are alternatives as bypassing agents for treatment of FVIII inhibitor patients.

One kind blood samples detection method using magnetic beads, completed with the following steps: (1) Get fresh clinical samples; (2)Put these specimen on coagulation analyzer, use magnetic beads and special adjustment reagents aiming at the whole blood specimens, measure four coagulations: Activated partial thromboplastin time (APTT), Prothrombin time (PT), Prothrombin time (TT), Fibrinogen (FIB). The advantages of this invention are: 1.The method is simple, time-saving and easy to technical staff. 2. Reduce costs and save centrifuges and other equipment, reduce errors; 3. It is efficient and suitable for the battlefield, natural disasters and remote mountainous areas, medical teams. Particularly, it's suitable for hemorrhagic diseases and natural disasters (such as hemophilia, etc.). 4. Save specimen volume. 5. Reflect the level of specimens of blood coagulation preciously and accurately.

The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX, utilizing an immortalized human cell line stably expressing viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins; an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.

The invention belongs to the field of biological medicine, and relates to a vesicle and application thereof. The source of the vesicle comprises stem cells or somatic cells, the marker of the vesicle comprises Syntaxin 4, and the vesicle is an induced vesicle. Compared with exosomes in MSCs, the vesicle provided by the invention can specifically express Syntaxin 4, and can be used for distinguishing MSCs-derived vesicles from characteristic markers of Exosomes. The method for preparing the vesicle has the advantages that the yield is high, 300-2000 vesicles can be produced by single MSCs, the preparation process is simple, the consumed time is short, the requirements on reagents and equipment are low, and the treatment effect is good. The vesicle can play a significant role in coagulation promotion in vitro, can significantly improve the bleeding tendency of hemophilia mice after being injected in vivo, and can be used for treatment for improving the bleeding tendency of hemophilia. Moreover, the vesicle can be discharged through skin and hair and is safe in vivo, so that the vesicle has a good application prospect.

The present invention refers to a recombinant human blood coagulation factor VIII protein and a composition containing it. The present invention also refers to the use of the protein or composition of the invention for manufacturing a medicine for treating hemophilia A. Additionally, the present invention refers to the method of obtaining a recombinant human blood coagulation factor VIII protein. A further object of the present invention is a recombinant protein obtained by the method described herein, and its use in the preparation of a medicine for the treatment of hemophilia A.

The present invention relates to nucleic acid expression cassettes and vectors containing liver-specific regulatory elements and codon-optimized factor IX or factor VIII transgenes, methods employing these expression cassettes and vectors and uses thereof. The present invention is particularly useful for applications using liver-directed gene therapy, in particular for the treatment of hemophilia A and B.

The invention discloses a method, primers and a kit for detecting inversion of the first intron of hemophilia A clotting factor VIII gene. The primers comprise primers SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3 for amplifying the Intlh-1 region of the clotting factor VIII gene and primers SEQ ID NO. 1, SEQ ID NO. 3 and SEQ ID NO. 4 for amplifying the Intlh-2 region of the clotting factor VIII gene. The method and the kit can be utilized to simply, efficiently and specifically detect the inversion of the first intron of the hemophilia A clotting factor VIII gene.

The present invention provides codon optimized Factor IX sequences, vectors and host cells comprising codon optimized Factor IX sequences, polypeptides encoded by codon optimized Factor IX sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor IX nucleic acid sequence or the polypeptide encoded thereby.

A freeze dried tranexamine acid powder used as antihemorrhagic injection for treating various hemorrhagic diseases contains tranexamine acid (0.05-10 wt. portions), freeze drying supporting agent (0-100) and pH regulator.

This invention relates to aryl or heteroaryl amido alkane derivatives of formula (I) in which Ar1 and Ar2 independently represent phenyl or a 5 or 6-membered heteroaromatic ring, R6 represents carboxyl or tetrazolyl, and the remaining variables are as defined in the text and claims, which are useful as an active ingredient of pharmaceutical preparations. The aryl or heteroaryl amido alkanes of the present invention have PGI2 antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with PGI2 activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases also relate to PGI2.

The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.

Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.

The invention belongs to the field of biological medicines, and in particular relates to a gene recombinant human blood coagulation factor VIII for treating hemophilia A. By performing zone B partially-deleted type mutation on a full-length blood coagulation factor VIII, the obtained novel gene recombinant human blood coagulation factor VIII product has a characteristic that the structure is more stable.

The invention discloses an F9 gene copy number variation detection kit which comprises a 2*PCR (Polymerase China Reaction) buffer solution, competitive DNA, PCR primer mixed liquor and Taq DNA polymerase. An AccuCopy technology has high precision, variable coefficient of being less than 5% and high result accuracy. Therefore, according to the F9 gene copy number variation detection kit developed by the AccuCopy technology, about 15 patients suffering hemophilia B with large deletion mutation is detected and found, and the clinical application effect is good.

The invention provides a traditional Chinese medicine preparation for treating hemophilia and a preparation method thereof. The traditional Chinese medicine is prepared from the following crude drugs of water chestnut, radix rubiae, buffalo horn, astragalus membranaceus, chickweed, codonopsis pilosula, hairyvein agrimony, herba violae, subprostrate sophora, celastrus aculeatus, dried rehamnnia root, fragrant hair grass, lalang grass rhizome, radix ranunculi ternate, placenta hominis, antelope horn, sweet wormwood, receptaculum nelumbinis, rhizoma bletillae, broken dense flowers and liquorice. The traditional Chinese medicine preparation has the beneficial effects that the traditional Chinese medicine preparation is a pure traditional Chinese medicine preparation, free of toxic and side effects, accurate in effect of bleeding pain, fast to become effective, good in treatment effect, convenient to take, available in materials, and low in drug cost, does not generate the drug dependence after being taken for a long period of time, and can help a sufferer get rid of whole blood and blood coagulation factors; the economical burden on treatment of the sufferer is reduced.